晚期胆道癌的不断变化的治疗场景:从化疗到分子点
L Kehmann1, M Jördens2, S H Loosen2
1Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin, Germany; Servier Deutschland GmbH, München, Germany.
ESMO open
|October 4, 2024
概括
胆道癌症的治疗正在进化,超越了化疗. 基因检测揭示了特定的突变,使得针对性疗法和改善的生存策略对于这一具有挑战性的肝癌.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 癌症研究 癌症研究
背景情况:
- 胆道癌 (BTC) 是一种具有挑战性的肝癌,预后不佳,往往晚诊断.
- 经典化疗可能不足,特别是在一线治疗失败后.
- 新型治疗策略对于改善患者存活率至关重要.
研究的目的:
- 审查目前和新兴的胆道癌症治疗方案.
- 探索基因改变在指导向治疗中的作用.
- 为个性化治疗决策强调分子分析.
主要方法:
- 对BTC化学疗法和向治疗的现有文献的审查.
- 在BTC中概述了常见和罕见的基因组变化.
- 讨论用于新型治疗方法的临床试验数据.
主要成果:
- 化疗与免疫检查点抑制剂的联合疗法在一线治疗中显示出有前途.
- 基于特定遗传变化的向疗法 (例如,IDH1/2,FGFR2,BRAF V600E,NTRK) 提供了新的治疗途径,特别是在二线环境中.
- 分子分析对于识别可操作的突变至关重要.
结论:
- 以分子分析为指导的向疗法代表了BTC治疗的重大进展.
- 需要进一步的研究来优化和扩大针对BTC的向治疗策略.
- 个性化医疗方法是改善这种侵袭性癌症患者治疗结果的关键.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489


